Press release
CROS NT appoints new Vice President for Germany
CROS is very excited to adding Mr. Freischläger's depth of industry expertise to the CROS team. "Bringing someone of Frank's knowledge to an already strong team will further strengthen our ability to grow in the right direction", said Dr. Paolo Morelli, General Manager of the CROS NT Group.
Mr. Freischläger has more than 20 years of clinical research experience in the pharmaceutical and CRO industries. He was leading groups in Clinical Data Management, Biostatistics & Programming, Medical Writing and Information Services for international CROs in Germany, the UK, Spain, Greece, Czech Republic and India. His experience includes a great variety of systems environments, therapeutic areas, clinical phases and trial designs. He holds a degree in statistics from the University of Dortmund.
CROS is a contract research organization offering a wide range of clinical research services to the pharmaceutical, biotechnology and medical devices industries. From Phase I to Phase IV, CROS focuses on delivering the highest quality data and meeting projected timelines.
To learn more about CROS, please visit http://www.crosnt.com, contact us by email info@crosnt.com or call our headquarters at +39 045 8202666.
CROS NT provides outsourced CDM, statistical, eCRF, ePRO and Hosting services across all phases of drug development. CROS NT offers global Pharmacovigilance solution for clinical safety and postmarket surveillance. With sophisticated technologies and processes CROS delivers on every project's specific requirements with a group of professionals.
CROS NT srl
Via Germania 2
37135 Verona
Italy
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CROS NT appoints new Vice President for Germany here
News-ID: 139677 • Views: …
More Releases from CROS NT
CROS NT WINS A "BEST PRESENTATION" AT PhUSE 2010
Verona, Italy (26 NOVEMBER 2010) – Stefano Vezzoli, part of CROS NT’s highly qualified and experienced biostatistics team, won Best Presentation in the area of Statistics and Pharmacokinetics at the Pharmaceutical Users Software Exchange (PhUSE) conference in Berlin, Germany. Vezzoli’s presentation was titled “Inference for the Location Shift in 3x3 Crossover Studies: the Median-Scaling Method”.
Vezzoli’s Paper Abstract
In the case of non-normal study outcomes, a nonparametric approach may be used…
CROS NT GROUP TO ATTEND THIRD ANNUAL ONCOLOGY CLINICAL TRIALS
Verona, Italy (23 NOVEMBER 2010) – The German subsidiary of the CROS NT Group, CROS DE GmbH, will be present at the Third Annual Oncology Clinical Trials in Munich, Germany from 29 November through 1 December. The therapeutic area of oncology is one of CROS NT’s areas of excellence regarding clinical trial experience, and the CROS DE management team is at the forefront of clinical trial consultancy in this field.…
CROS NT Group launches Arithmos s.r.l. to keeping up with the new Innovation’s …
CROS NT Group launches Arithmos s.r.l., a start up company created at the beginning of 2010 with the aim to play an active role as information technology service provider within the pharmaceutical and biotechnology environment.
Inheriting CROS NT’s 15 years experience and developing a strong sensibility for innovation investments, today Arithmos is a valuable partner to optimize companies performances and accelerate their growth into the market in an accurate, safe and…
CROS NT Announces its Expansion into German Market Creating CROS DE GmbH
CROS NT is pleased to announce its expansion into Europe through the creation of CROS DE GmbH, a new wholly-owned subsidiary based in Augsburg, Germany. The company, born from the experience of a German-based CRO, Estimate GmbH, is specialized in providing statistical services to pharmaceuticals and biotechnology industries.
Estimate enrich CROS NT with its expertise and a particular excellence concerning the oncology and dermatology-related research. Estimate was found in 1992…
More Releases for CRO
Global Veterinary CRO & CDMO Market Size & Trends
According to a new market research report published by Global Market Estimates, the global veterinary CRO & CDMO market is expected to grow at a CAGR of 9.1% from 2023 to 2028.
The growing awareness regarding the importance of animal health and welfare has led to increased investments in veterinary pharmaceutical research and development. This awareness is driven by the rising concern for the well-being of pets, livestock, and animals used…
Global Contract Research Organization (CRO) Services Market
According to a new market research report published by Global Market Estimates, the Global Contract Research Organization (CRO) Services Market is expected to grow at a CAGR of 10.2% from 2023 to 2028.
The growth of the contract research organization (CRO) Services Market is fuelled by factors including the rising preference for outsourcing clinical trials, increasing investments in research and development by pharmaceutical and biopharmaceutical companies, the growing complexities in drug…
Contract Research Organization (CRO) Services Market - Efficiency, Expertise, Ex …
Newark, New Castle, USA: The "Contract Research Organization (CRO) Services Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Contract Research Organization (CRO) Services Market: https://www.growthplusreports.com/report/contract-research-organization-cro-services-market/7630
This latest report…
Biopharmaceutical CMO and CRO Market
The Biopharmaceutical CMO and CRO Market crossed US$ 32.25 billion in 2022 and is expected to hit US$ 54.13 billion by 2030, recording a CAGR of 6.5% during the forecast period
Pharmaceutical and biotech companies focus on R&D activities to innovate new molecules and therapeutic platforms to deal with chronic diseases and rare ailments; they also extensively invest in R&D activities to develop various therapeutic applications with strong medical and commercial…
Pracedo Promote Ellie Copp To CRO
Pracedo, a Mashfrog Group company that provides Salesforce consultancy and digital transformation to charities, NGOs, and enterprise customers, promotes Ellie Copp to Chief Revenue Officer.
Pracedo announced Ellie Copp as its new Chief Revenue Officer (CRO). Ellie joined Pracedo in 2019 and most recently held the position of Sales and Marketing Director. As CRO, she will continue to lead the commercial teams by overseeing all revenue-generating activities as Pracedo continues…
Partnership factors in sponsor – CRO relationships
Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market. CRO’s have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money.
There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate…
